Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Brown University | OTHER |
| Case Western Reserve University | OTHER |
| Genentech, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Influenza outbreaks are a prevalent event in nursing homes (NHs). We will study baloxavir compared to oseltamivir when used for influenza prophylaxis when facilities identify an index incident case of influenza. This study will help guide nursing home's decision making and demonstrate the effectiveness of a novel antiviral for preventing influenza outbreaks.
A random study sample of about 1000 U.S. nursing homes (NHs), housing approximately 112,000 overall residents and 92,000 over the age of 65 years, of whom 64,500 are long-stay NH residents, will be recruited for the study. Participating facilities will be randomly allocated in a 1:1 ratio to oseltamivir or baloxavir for antiviral treatment and prophylaxis. Primary study data provided by facilities monthly during the influenza season will support primary and secondary endpoints along with administrative claims and public use datasets containing information on facility characteristics.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oseltamivir | Active Comparator | Nursing homes randomized to receive oseltamivir for treatment and chemoprophylaxis for influenza. |
|
| Baloxavir | Experimental | Nursing homes randomized to receive baloxavir for treatment and chemoprophylaxis for influenza. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oseltamivir | Drug | Nursing home residents and staff 18 years and older are allocated to receive oseltamivir for treatment and chemoprophylaxis for influenza. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Total number of ILI cases defined, following the index influenza case identification in nursing homes randomized to baloxavir or oseltamivir | To demonstrate the non-inferiority of prophylactic baloxavir vs. oseltamivir to prevent influenza-like illness (ILI) after an index influenza case in nursing homes. | Up to 8 months each influenza season |
| Measure | Description | Time Frame |
|---|---|---|
| Outbreak duration defined as the time of the first laboratory-confirmed case of influenza to 7 days following the last identified case of influenza-like illness requiring treatment with baloxavir or oseltamivir | To determine the difference in total outbreak duration for each outbreak occurring in nursing homes randomized to offer either single-dose baloxavir or oseltamivir for outbreak abatement during the 2021-2022 influenza season. |
Not provided
Inclusion Criteria:
- Medicare-certified NHs in any location in the United States with at least 50 long-stay residents 18 years of age or older.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Insight Therapeutics, LLC | Norfolk | Virginia | 23510 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D053139 | Oseltamivir |
| C000628402 | baloxavir |
| ID | Term |
|---|---|
| D000081 | Acetamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D053138 | Cyclohexenes |
| D003510 |
Not provided
Not provided
Pragmatic Cluster Randomized Clinical Trial
Not provided
Not provided
Not provided
Not provided
| Baloxavir | Drug | Nursing home residents and staff 18 years and older are allocated to receive baloxavir for treatment and chemoprophylaxis for influenza. |
|
| Up to 8 months each influenza season |
| Facility-level data on antiviral courses of treatment administered from Medication Administration Records | To determine the difference in number of courses of treatment of baloxavir or oseltamivir needed for outbreak control in nursing homes randomized to baloxavir or oseltamivir. | Up to 8 months each influenza season |
| Hospitalizations from Minimum Data Set (MDS) 3.0 (interim) and Medicare A claims | To determine the difference in respiratory-related hospitalization rates during the 2021-2022 influenza season experienced by long-stay nursing home residents 65 and older living in nursing homes randomized to either baloxavir or oseltamivir. | Up to 8 months each influenza season |
| Mortality from Medicare Vital Status File | To determine the differences in long-stay residents' mortality rates in nursing homes randomized to either baloxavir or oseltamivir. | Up to 8 months each influenza season |
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
| Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |